Oddity Tech Ltd. (NASDAQ:ODD) is considered one of the most oversold mid-cap stocks to buy according to hedge funds. KeyBanc Capital Markets analyst Scott Schoenhaus maintained an Overweight rating on Oddity Tech but lowered the price target from $90 to $80 on October 8, 2025. The firm highlighted Oddity’s potential upside driven by its proprietary hyperspectral + biotech stack and the upcoming Q4 launch of a medical-grade skin and body care brand. Despite the target cut, KeyBanc remains bullish on the company’s ability to scale both top-line and margin expansion, emphasizing revenue growth above 20% and long-term EBITDA margins above 20% are achievable. Oddity Tech Ltd. is an AI-driven beauty and wellness platform integrating machine learning, proprietary data, and biotech R&D to personalize consumer products in the skincare, cosmetics, and wellness space.

Read more at Yahoo Finance: KeyBanc Trims Target but Stays Bullish on Oddity’s Beauty-Tech Play